VolitionRX (NYSEAMERICAN:VNRX) Posts Quarterly Earnings Results, Misses Estimates By $0.15 EPS

VolitionRX (NYSEAMERICAN:VNRX) posted its quarterly earnings data on Thursday. The medical research company reported ($0.85) earnings per share for the quarter, missing the consensus estimate of ($0.70) by ($0.15), FiscalAI reports. The company had revenue of $0.40 million during the quarter, compared to analyst estimates of $0.41 million.

VolitionRX Stock Down 5.7%

VNRX traded down $0.04 during trading on Thursday, reaching $0.63. 825,091 shares of the company’s stock were exchanged, compared to its average volume of 471,390. VolitionRX has a fifty-two week low of $0.60 and a fifty-two week high of $15.10. The business has a 50 day moving average price of $1.19 and a 200 day moving average price of $2.79. The company has a market capitalization of $5.44 million, a P/E ratio of -0.15 and a beta of 1.16.

Analyst Ratings Changes

Several research analysts have commented on VNRX shares. D. Boral Capital reaffirmed a “hold” rating on shares of VolitionRX in a research report on Monday, April 20th. Citigroup cut VolitionRX to a “hold” rating in a research report on Monday, April 20th. Benchmark restated a “hold” rating on shares of VolitionRX in a research note on Tuesday, June 2nd. Finally, Maxim Group reaffirmed a “buy” rating and set a $4.00 target price on shares of VolitionRX in a research report on Thursday, June 18th. Two equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $28.00.

Hedge Funds Weigh In On VolitionRX

A number of hedge funds have recently modified their holdings of the stock. Armistice Capital LLC raised its stake in VolitionRX by 10.4% during the third quarter. Armistice Capital LLC now owns 9,380,425 shares of the medical research company’s stock worth $6,367,000 after acquiring an additional 887,351 shares in the last quarter. Geode Capital Management LLC boosted its stake in shares of VolitionRX by 9.8% in the 4th quarter. Geode Capital Management LLC now owns 963,986 shares of the medical research company’s stock valued at $246,000 after purchasing an additional 85,816 shares in the last quarter. Citadel Advisors LLC grew its holdings in shares of VolitionRX by 70.1% in the 3rd quarter. Citadel Advisors LLC now owns 329,520 shares of the medical research company’s stock worth $224,000 after purchasing an additional 135,775 shares during the last quarter. Squarepoint Ops LLC bought a new stake in shares of VolitionRX in the 4th quarter worth about $34,000. Finally, Jane Street Group LLC acquired a new stake in shares of VolitionRX during the 4th quarter worth about $28,000. 8.09% of the stock is owned by institutional investors and hedge funds.

VolitionRX Company Profile

VolitionRX, traded as VNRX on the NYSE American exchange, is a pioneering life sciences company focused on the development and commercialization of minimally invasive diagnostic tests for the early detection of cancer and other diseases. Utilizing proprietary technology to analyze circulating nucleosomes in blood samples, the company’s platform identifies disease-specific epigenetic and biochemical signatures. By offering blood-based screening solutions, VolitionRX aims to deliver alternatives to invasive, costly and time-consuming procedures, potentially improving patient outcomes through earlier diagnosis.

The company’s flagship product suite, branded as Nu.Q, comprises assays designed to detect biomarkers associated with a range of malignancies, including colorectal, lung and pancreatic cancers, as well as other systemic conditions.